At a glance
The respiratory vaccine codes and crosswalk tables for RSV, COVID-19, and Influenza are provided in the following summary tables.
Respiratory Syncytial Virus (RSV) Codes and Crosswalks
The following table includes the RSV codes and crosswalks included in the CDC IIS Vaccine Code Sets. Note that the CPT codes shown are not mapped to the NDC codes, but are mapped to the CVX codes shown. CPT codes provided in the vaccine code sets are to assist with code categorizations and are not intended to represent billable codes.
Email Updates
Download the RSV Crosswalk table
Respiratory Syncytial Virus (RSV) Vaccine Codes Fall 2024
| CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 303 | Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free | Arexvy | GlaxoSmithKline Biologicals SA | SKB | 58160-0848-11 | 58160-0723-03 | VIAL, 0.5 mL, reconstituted | 90679 | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use |
| 305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | Abrysvo | Pfizer Laboratories Div Pfizer Inc | PFR | 00069-0344-01 00069-0344-05 00069-0344-10 |
00069-0207-01 | VIAL, 0.5 mL, reconstituted | 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
| 305 | Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free | Abrysvo | Pfizer Laboratories Div Pfizer Inc | PFR | 00069-2465-01 00069-2465-10 |
00069-2465-19 | VIAL, 0.5 mL, SINGLE-DOSE | 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use |
| 326 | Respiratory syncytial virus (RSV), mRNA, injectable, preservative free | mRESVIA | Moderna US, INC. | MOD | 80777-0345-96 80777-0345-90 |
80777-0345-01 | SYRINGE, 0.5 mL | 90683 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use |
Respiratory Syncytial Virus (RSV) Monoclonal Antibody Codes Fall 2024 (*)
| CVX Code | CVX Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 306 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-0575-15 | 49281-0575-00 | SYRINGE, 0.5 mL | 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use |
| 307 | Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months | BEYFORTUS | Sanofi Pasteur Inc. | PMC | 49281-0574-15 | 49281-0574-88 | SYRINGE, 1 mL | 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use |
(*) The BEYFORTUS nirsevimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines.
Respiratory Syncytial Virus (RSV) Unspecified Codes
| CVX Code | CVX Description | CVX Note |
|---|---|---|
| 314 | Respiratory syncytial virus (RSV) vaccine, unspecified | Unspecified, for historic records where the specific vaccine administered is not known |
| 315 | Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified | Unspecified, for historic records where the specific RSV MAB administered is not known |
| 304 | Respiratory syncytial virus (RSV), unspecified | Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered |
Guidance relating to RSV vaccines can be found at Home page for MMWR | MMWR (cdc.gov)
On July 17, 2023, the Food and Drug Administration licensed Nirsevimab (Beyfortus), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants and young children. It is anticipated that the Advisory Committee on Immunization Practices (ACIP) will vote on potential recommendations for use of this product and its inclusion in the Vaccines for Children (VFC) program at the August 3rd ACIP meeting.
New codes listed above have been added in anticipation of potential recommendations. More information to support integration into VFC, as well as details around vaccine codes, Clinical Decision Support for Immunization (CDSi), and any data collection requirements will be published as they become available.
Fall 2023 COVID-19 Vaccine Codes and Crosswalks
The following table provides a preview and summary of the vaccine codes and crosswalks for Fall 2023 COVID-19 vaccines.
Note: Codes in the following table are effective and published in the full vaccine code sets only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). Additional code details and fields values are included in the vaccine code sets published.
Download the Fall 2023 COVID-19 Vaccine Code Crosswalk table
| Manufacturer (MVX) | Product Label Tradename (*) | CVX Code | CVX Term Description | CVX Short Description | NDC Virus Strain | UoS NDC10 UoS NDC11 |
Packaging | UoU NDC10 UoU NDC11 |
Age Cohort; Presentation |
CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer (PFR) |
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 0069-2362-10 00069-2362-10 |
CARTON, 10 SINGLE-DOSE VIALS | 0069-2362-01 00069-2362-01 |
Ages 12 years and older; VIAL, SINGLE-DOSE, 30 mcg/0.3 mL |
91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula), no freeze formulation | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 0069-2377-10 00069-2377-10 | CARTON, 10 PRE-FILLED GLASS SYRINGES | 0069-2377-01 00069-2377-01 | Ages 12 years and older; GLASS SYRINGE, SINGLE-DOSE, 30 mcg/0.3 mL - DO NOT FREEZE |
91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 0069-2392-10 00069-2392-10 |
CARTON, 10 PRE-FILLED PLASTIC SYRINGES | 0069-2392-01 00069-2392-01 |
Ages 12 years and older; PLASTIC SYRINGE, PRE-FILLED, 30 mcg/0.3 mL |
91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) | 310 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 59267-4331-2 59267-4331-02 |
CARTON, 10 SINGLE-DOSE VIALS | 59267-4331-1 59267-4331-01 |
Ages 5 through 11 years; VIAL, SINGLE-DOSE, 10 mcg/0.3 mL |
91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Pfizer (PFR) |
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) | 308 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 59267-4315-2 59267-4315-02 |
CARTON, 10 MULTI-DOSE VIALS | 59267-4315-1 59267-4315-01 |
Ages 6 months through 4 years; VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION |
91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| Novavax (NVX) |
Novavax COVID-19 Vaccine, Adjuvanted | 313 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80631-105-02 80631-0105-02 |
CARTON, 2 MULTI-DOSE VIALS | 80631-105-01 80631-0105-01 |
Ages 12 years and older; VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL |
91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-102-95 80777-0102-95 |
CARTON, 10 SINGLE-DOSE VIALS | 80777-102-04 80777-0102-04 |
Ages 12 years and older; VIAL, SINGLE-DOSE, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-102-96 80777-0102-96 |
CARTON, 10 PRE-FILLED SYRINGES | 80777-102-01 80777-0102-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-102-93 80777-0102-93 |
CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES | 80777-102-01 80777-0102-01 |
Ages 12 years and older; SYRINGE, PRE-FILLED, 50 mcg/0.5 mL |
91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna (MOD) |
Moderna COVID-19 Vaccine | 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | SARS-CoV-2 virus strain Omicron XBB.1.5 | 80777-287-92 80777-0287-92 |
CARTON, 10 SINGLE-DOSE VIALS | 80777-287-07 80777-0287-07 |
Ages 6 months through 11 years; VIAL, SINGLE-DOSE, 25 mcg/0.25 mL |
91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |
(*) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is to be provided under Emergency Use Authorization (EUA), once FDA EUA issuance is received. Other tradenames are for vaccine products to be provided under BLA licensure, once approved.
(*) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is to be provided under Emergency Use Authorization (EUA), once FDA EUA issuance is received. Other tradenames are for vaccine products to be provided under BLA licensure, once approved.
Other COVID-19 Vaccine Related Codes and Links
Information regarding currently active EUA Recipient and Caregiver Fact Sheet URLs and Codes can be found here.
Registered users can access COVID-19 vaccine lot numbers and expiration dates provided to CDC by the vaccine manufacturer.
Information regarding Previous COVID-19 pandemic Emergency Use Authorization (EUA) and BLA codes and crosswalks can be found here.
2024/2025 Seasonal Influenza Codes and Crosswalk
This format includes all seasonal influenza vaccines for the 2024/2025 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.
(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown. These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.
Download the Seasonal Influenza Crosswalk table
Influenza Vaccines for Season 2024/2025 (Northern Hemisphere)
| CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 141 | Influenza, split virus, trivalent, preservative | Afluria | Seqirus PTY LTD. | SEQ | 33332-0124-10 | 33332-0124-11 | VIAL, 5 mL, MULTI-DOSE | 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
| 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use | ||||||||
| 140 | Influenza, split virus, trivalent, PF | Afluria | Seqirus PTY LTD. | SEQ | 33332-0024-03 | 33332-0024-04 | SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 168 | Influenza, adjuvanted, trivalent, PF | FLUAD | Seqirus, Inc. | SEQ | 70461-0024-03 | 70461-0024-04 | SYRINGE, 0.5mL | 90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use |
| 140 | Influenza, split virus, trivalent, PF | FLUARIX | GlaxoSmithKline Biologicals SA | SKB | 58160-0884-52 | 58160-0884-41 | SYRINGE, 0.5mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 155 | Influenza, recombinant, trivalent, PF | FLUBLOK TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0724-10 | 49281-0724-88 | SYRINGE, 0.5 mL | 90673 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use |
| 153 | Influenza, MDCK, trivalent, PF | Flucelvax | Seqirus Inc. | SEQ | 70461-0654-03 | 70461-0654-04 | SYRINGE, 0.5 mL | 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
| 320 | Influenza, MDCK, trivalent, preservative | Flucelvax | Seqirus Inc. | SEQ | 70461-0554-10 | 70461-0554-11 | VIAL, 5 mL, MULTI-DOSE | 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
| 140 | Influenza, split virus, trivalent, PF | FLULAVAL | ID Biomedical Corporation of Quebec | IDB | 19515-0810-52 | 19515-0810-41 | SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 135 | Influenza, high-dose, trivalent, PF | FLUZONE HIGH DOSE NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0124-65 | 49281-0124-88 | SYRINGE, 0.5 mL | 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use |
| 141 | Influenza, split virus, trivalent, preservative | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0641-15 | 49281-0641-78 | VIAL, 5 mL, MULTI-DOSE | 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
| 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use | ||||||||
| 140 | Influenza, split virus, trivalent, PF | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0424-50 | 49281-0424-88 | SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
| 111 | Influenza, live, trivalent, intranasal | FluMist trivalent | MedImmune, Inc. | MED | TDB (*) | TBD (*) | APPLICATOR 0.2 mL | 90660 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use |
Southern Hemisphere 2024 Influenza Season
| CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CPT Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|
| 200 | influenza, Southern Hemisphere, pediatric, preservative free | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | NA | NA | SYRINGE, 0.25 mL | NA | NA |
| 201 | influenza, Southern Hemisphere, preservative free | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0324-50 | 49281-0324-88 | SYRINGE, 0.5 mL | NA | NA |
| 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0398-15 | 49281-0398-78 | VIAL, MULTI-DOSE, 5 mL | NA | NA |
| 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | FLUZONE High-Dose Quadrivalent Southern Hemisphere | Sanofi Pasteur Inc. | PMC | 49281-0379-50 | 49281-0933-88 | SYRINGE, .7 mL | NA | NA |